Lonza and Antharis Therapeutics ink licensing deal for dual-payload ADCs targeting GI cancers
Antharis gains rights to Lonza's clinically validated dual-payload technology, combining it with proprietary antibody engineering to advance a lead ADC programme entering clinical trials for gastrointestinal cancers